๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

23 recruiting trials

for Relapsed/Refractory Small Cell Lung Cancer

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma NCT03460977Phase 185 sites๐Ÿ“ Tucson๐Ÿ“ Tucson๐Ÿ“ Tucson Pfizer ยท Tests: Mevrometostat (PF-06821497), Enzalutamide, Itraconazole Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites๐Ÿ“ Tucson๐Ÿ“ New Haven๐Ÿ“ Baltimore Calico Life Sciences LLC ยท Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deatโ€ฆ Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC NCT05669846Phase 21 site๐Ÿ“ Pittsburgh Diwakar Davar ยท Tests: Healthy Donor Fecal Microbiota Transplant (hdFMT), Pembrolizumab A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) NCT07488923Phase 17 sites๐Ÿ“ St Louis๐Ÿ“ Hackensack๐Ÿ“ New York Moonlight Bio, Inc ยท Tests: ML261 A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer NCT07325136Phase 1, Phase 213 sites๐Ÿ“ Detroit๐Ÿ“ Buffalo๐Ÿ“ Durham Bristol-Myers Squibb ยท Tests: BMS-986525, Pumitamig A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors NCT06956690Phase 1, Phase 27 sites๐Ÿ“ La Jolla๐Ÿ“ Indianapolis๐Ÿ“ Farmington Hills Hummingbird Bioscience ยท Tests: ENV-501 TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors NCT07713732Phase 13 sites๐Ÿ“ Camperdown๐Ÿ“ Malvern๐Ÿ“ Nedlands Treeline Biosciences, Inc. ยท Tests: TLN-499, Venetoclax Evaluation of XYA02 in Patients With Advanced Solid Tumors NCT07670312Phase 1, Phase 25 sites๐Ÿ“ Sydney๐Ÿ“ Sydney๐Ÿ“ Melbourne XYone Therapeutics, Inc ยท Tests: XYA02 Phase I Clinical Study of ฮฑ-PD-L1/DLL3 CAR-T in Patients With R/R SCLC NCT06348797Phase 11 site๐Ÿ“ Chengdu Sichuan University ยท Tests: ฮฑ-PD-L1/4-1BB DLL3 CAR-T (BHP01) This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. NCT07249879Phase 12 sites๐Ÿ“ Beijing๐Ÿ“ Beijing Cancer Institute and Hospital, Chinese Academy of Medical Sโ€ฆ ยท Tests: GC511B CAR-T Cell Injection TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC NCT07246304EARLY Phase 11 site๐Ÿ“ Nanjing TCRCure Biopharma Ltd. ยท Tests: TC-D101 CAR-T DAREONโ„ข-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers NCT05882058Phase 259 sites๐Ÿ“ Mobile๐Ÿ“ Phoenix๐Ÿ“ Los Angeles Boehringer Ingelheim ยท Tests: BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871Phase 1, Phase 25 sites๐Ÿ“ Dothan๐Ÿ“ Grand Rapids๐Ÿ“ Omaha Radiopharm Theranostics, Ltd ยท Tests: 177Lu-BetaBart, BetaBart + unlabeled BetaBart TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies NCT06484816Phase 11 site๐Ÿ“ Hangzhou Shenzhen TargetRx Co., Ltd. ยท Tests: TGRX-1942 A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) NCT06780137Phase 1, Phase 248 sites๐Ÿ“ Aurora๐Ÿ“ Miami๐Ÿ“ Chicago Merck Sharp & Dohme LLC ยท Tests: Gocatamig, Ifinatamab Deruxtecan (I-DXd), Durvalumab Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease NCT07509034Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187Phase 110 sites๐Ÿ“ Denver๐Ÿ“ Orlando๐Ÿ“ Sarasota Dren Bio ยท Tests: DR-0202 Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) NCT07480213Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-DART-NK01 (DLL3/CD56 CAR-NK cells), Lymphodepleting chemotherapy Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer NCT06922539Phase 12 sites๐Ÿ“ Los Angeles๐Ÿ“ Detroit SciTech Development, Inc. ยท Tests: Fenretinide, Fenretinide A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer NCT02889666Phase 13 sites๐Ÿ“ Changchun๐Ÿ“ Shanghai๐Ÿ“ Shanghai Shanghai Jiao Tong University School of Medicine ยท Tests: Cisplatin, Carboplatin, Docetaxel, Gemcitabine/Carboplatin, Gemcitabine/Cisplatin A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer NCT07365241Phase 372 sites๐Ÿ“ Birmingham๐Ÿ“ Mobile๐Ÿ“ Goodyear AbbVie ยท Tests: ABBV-706, Topotecan, Topotecan, Lurbinectedin, Amrubicin Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) NCT07744256Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-DART-NK01, Lymphodepleting chemotherapy
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy